243 related articles for article (PubMed ID: 35724798)
1. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
3. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.
Lu S; Zhou J; Jian H; Wu L; Cheng Y; Fan Y; Fang J; Chen G; Zhang Z; Lv D; Jiang L; Wu R; Jin X; Zhang X; Zhang J; Xie C; Sun G; Huang D; Cui J; Guo R; Han Z; Chen Z; Liang J; Zhuang W; Hu X; Zang A; Zhang Y; Cang S; Lan Y; Chen X; Liu L; Li X; Chen J; Ma R; Guo Y; Sun P; Tian P; Pan Y; Liu Z; Cao P; Ding L; Wang Y; Yuan X; Wu P
Lancet Respir Med; 2023 Oct; 11(10):905-915. PubMed ID: 37244266
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
[TBL] [Abstract][Full Text] [Related]
6. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
9. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
11. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Yang JC; Ahn MJ; Kim DW; Ramalingam SS; Sequist LV; Su WC; Kim SW; Kim JH; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin CC; Mann H; Cantarini M; Ghiorghiu S; Jänne PA
J Clin Oncol; 2017 Apr; 35(12):1288-1296. PubMed ID: 28221867
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
